Citations

Clear

4847 citation(s) found for "Tu, Eric".

P‐020: Regional gray matter reductions in Alzheimer's dementia and amnestic mild cognitive impairment: Preliminary findings from the Alzheimer's disease neuroimaging initiative using voxel‐based morphometry
Alexander, Gene E. , Reiman, Eric M. , Aschenbrenner, Melaney, Hanson, Krista D., Kornak, John , Schuff, Norbert, Weiner, Michael W. , Chen, Kewei , Merkley, Tricia L. , Dale, Anders M. , Bernstein, Matt A. , Fox, Nick C. , Thompson, Paul M. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | June 4, 2007 | Volume: 3 | Issue: 3S_Part_1 | Pages: No page available

10.1016/j.jalz.2007.04.236 Get It

O1–05–03: PET measurements of posterior cingulate glucose metabolism are superior to MRI measurements of hippocampal volume in distinguishing cognitively normal persons at differential genetic risk for Alzheimer's disease
Reiman, Eric M. , Alexander, Gene E. , Reschke, Cole, Lee, Wendy , Smilovici, Oded, Buckley, Shannon, Sacrey, Diana Truran, Schuff, Norbert, Müller, Stig , Weiner, Michael W. , Caselli, Richard J., Chen, Kewei , Smilovici, Oded

Mayo Clinic

Alzheimer's & Dementia | June 4, 2007 | Volume: 3 | Issue: 3S_Part_3 | Pages: No page available

10.1016/j.jalz.2007.04.070 Get It

Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Can
Olsen, Elise A. , Vonderheid, Eric C. , Pimpinelli, Nicola , Knobler, Robert , Zackheim, Herschel, Estrach, Teresa , Lamberg, Stanford, Wood, Gary S. , Dummer, Reinhard , Burg, Günter , Heald, Peter, Pittelkow, Mark R. , Bernengo, M.G., Sterry, Wolfram, Laroche, L. , Trautinger, Franz , Whittaker, Sean , Willemze, Rein , Kim, Youn , Zackheim, Herschel, Duvic, Madeleine , Lamberg, Stanford, Ranki, Annamari , Sterry, Wolfram

Mayo Clinic

Blood | May 31, 2007 | Volume: 110 | Issue: 6 | Pages: 1713-1722

10.1182/blood-2007-03-055749 | PMID 17540844 Get It

Abstract The ISCL/EORTC recommends revisions to the Mycosis Fungoides Cooperative Group classification and staging system for cutaneous T-cell lymphoma (CTCL). These revisions are made to incorporate advances related to tumor cell biology and diagnostic techniques as pertains to mycosis fungoides (MF) and Sézary syndrome (SS) since the 1979 publication of the original guidelines, to clarify certain variables that currently impede effective interinstitution and interinvestigator communication and/or the development of standardized clinical trials in MF and SS, and to provide a platform for tracking other variables of potential prognostic significance. Moreover, given the difference in prognosis and clinical characteristics of the non-MF/non-SS subtypes of cutaneous lymphoma, this revision pertains specifically to MF and SS. The evidence supporting the revisions is discussed as well as recommendations for evaluation and staging procedures based on these revisions.
Predicting the Outcome of Salvage Radiation Therapy for Recurrent Prostate Cancer After Radical Prostatectomy
Stephenson, Andrew J. , Scardino, Peter T. , Kattan, Michael W. , Pisansky, Thomas M. , Slawin, Kevin M., Klein, Eric A. , Anscher, Mitchell S. , Michalski, Jeff M. , Lin, Daniel W. , Forman, Jeffrey D., Zeléfsky, Michael J. , Kestin, Larry L. , Roehrborn, Claus G. , Catton, Charles , DeWeese, Theodore L. , Liauw, Stanley L. , Valicenti, Richard K., Kuban, Deborah A., Pollack, Alan , Sandler, Howard M. , Klein, Eric A , Liauw, Stanley L , Kattan, Michael W

Mayo Clinic

Journal of Clinical Oncology | May 19, 2007 | Volume: 25 | Issue: 15 | Pages: 2035-2041

10.1200/jco.2006.08.9607 | PMID 17513807 Get It

Purpose An increasing serum prostate-specific antigen (PSA) level is the initial sign of recurrent prostate cancer among patients treated with radical prostatectomy. Salvage radiation therapy (SRT) may eradicate locally recurrent cancer, but studies to distinguish local from systemic recurrence lack adequate sensitivity and specificity. We developed a nomogram to predict the probability of cancer control at 6 years after SRT for PSA-defined recurrence. Patients and Methods Using multivariable Cox regression analysis, we constructed a model to predict the probability of disease progression after SRT in a multi-institutional cohort of 1,540 patients. Results The 6-year progression-free probability was 32% (95% CI, 28% to 35%) overall. Forty-eight percent (95% CI, 40% to 56%) of patients treated with SRT alone at PSA levels of 0.50 ng/mL or lower were disease free at 6 years, including 41% (95% CI, 31% to 51%) who also had a PSA doubling time of 10 months or less or poorly differentiated (Gleason grade 8 to 10) cancer. Significant variables in the model were PSA level before SRT (P < .001), prostatectomy Gleason grade (P < .001), PSA doubling time (P < .001), surgical margins (P < .001), androgen-deprivation therapy before or during SRT (P < .001), and lymph node metastasis (P = .019). The resultant nomogram was internally validated and had a concordance index of 0.69. Conclusion Nearly half of patients with recurrent prostate cancer after radical prostatectomy have a long-term PSA response to SRT when treatment is administered at the earliest sign of recurrence. The nomogram we developed predicts the outcome of SRT and should prove valuable for medical decision making for patients with a rising PSA level.
Immune Mechanisms in Non–Hodgkin Lymphoma: Joint Effects of the TNF G308A and IL10 T3575A Polymorphisms with Non–Hodgkin Lymphoma Risk Factors
Wang, Sophia , Cerhan, James R. , Colt, Joanne S., Morton, Lindsay M. , Severson, Richard K., Rothman, Nathaniel , Hartge, Patricia, Cozen, Wendy , Engels, Eric A. , Davis, Scott , Chanock, Stephen Jacob , Cerhan, James R , Morton, Lindsay M , Wang, Sophia S

Mayo Clinic

Cancer Research | May 18, 2007 | Volume: 67 | Issue: 10 | Pages: 5042-5054

10.1158/0008-5472.can-06-4752 | PMID 17510437 Get It

Abstract Two common single nucleotide polymorphisms in immunoregulatory genes (TNF G308A, rs1800629 and IL10 T3575A, rs1800890) have been recently reported as risk factors for non–Hodgkin lymphoma (NHL) in a large pooled analysis. We systematically investigated the effects of other established NHL risk factors in relation to the tumor necrosis factor (TNF) G308A or interleukin 10 (IL10) T3575A genotypes. We calculated odds ratios (OR) and 95% confidence intervals (95% CI) from 1,172 cases and 982 population-based controls in a U.S. multicenter study. We investigated NHL overall and two common subtypes [diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma]. NHL risks were increased among those with both an autoimmune condition and the TNF G308A GA/AA (ORNHL, 2.1; 95% CI, 1.0–4.2) or the IL10 T3575A TA/AA genotype (ORNHL, 1.6; 95% CI, 0.9–2.6) compared with individuals without an autoimmune condition and with the common TNF G308A GG or IL10 T3575A TT genotype, respectively; results were similar for DLBCL and follicular lymphoma. We found that elevated DLBCL risk associated with last-born status was more pronounced among those with TNF G308A GA/AA (ORDLBCL, 2.7; 95% CI, 1.1–6.4) or IL10 T3575A TA/AA (ORDLBCL, 2.9; 95% CI, 1.6–5.2). Similarly, elevated DLBCL risk associated with obesity (body mass index, ≥35 versus &lt;25 kg/m2) was observed only among those with TNF G308A GA/AA (ORDLBCL, 2.5; 95% CI, 1.1–5.7) or IL10 T3575A TA/AA genotypes (ORDLBCL, 2.0; 95% CI, 1.1–3.5). These exploratory results require replication but provide evidence that autoimmune conditions, late birth order, and obesity act partly through a common inflammatory pathway, posing a greater risk to individuals with variant TNF and IL10 genotypes than those with wild-type alleles. [Cancer Res 2007;67(10):5042–54]
Personalized Medicine for High Blood Pressure
Schwartz, Gary L. , Boerwinkle, Eric , Turner, Stephen T.

Mayo Clinic

Hypertension | May 1, 2007 | Volume: 50 | Issue: 1 | Pages: 1-5

10.1161/hypertensionaha.107.087049 | PMID 17470720 Get It

Quantitating tissue specificity of human genes to facilitate biomarker discovery
Vasmatzis, George , Klee, Eric W. , Kube, Dagmar Marie, Therneau, Terry M. , Kosari, Farhad

Mayo Clinic

Bioinformatics | March 24, 2007 | Volume: 23 | Issue: 11 | Pages: 1348-1355

10.1093/bioinformatics/btm102 | PMID 17384019 Get It

AbstractWe describe a method to identify candidate cancer biomarkers by analyzing numeric approximations of tissue specificity of human genes. These approximations were calculated by analyzing predicted tissue expression distributions of genes derived from mapping expressed sequence tags (ESTs) to the human genome sequence using a binary indexing algorithm. Tissue-specificity values facilitated high-throughput analysis of the human genes and enabled the identification of genes highly specific to different tissues. Tissue expression distributions for several genes were compared to estimates obtained from other public gene expression datasets and experimentally validated using quantitative RT-PCR on RNA isolated from several human tissues. Our results demonstrate that most human genes (∼98%) are expressed in many tissues (low specificity), and only a small number of genes possess very specific tissue expression profiles. These genes comprise a rich dataset from which novel therapeutic targets and novel diagnostic serum biomarkers may be selected.Contact: vasm@mayo.eduSupplementary information: Supplementary data are available at Bioinformatics online.
CT Findings of Granulomatous Pneumonitis Secondary to Mycobacterium avium-intracellulare Inhalation: “Hot Tub Lung”
Hartman, Thomas E. , Jensen, Eric A., Tazelaar, Henry D. , Hanak, Viktor, Ryu, Jay H. , Tazelaar, Henry D. , Ryu, Jay H

Mayo Clinic

American Journal of Roentgenology | March 21, 2007 | Volume: 188 | Issue: 4 | Pages: 1050-1053

10.2214/ajr.06.0546 | PMID 17377045 Get It

Genetic Determinants of Emphysema Distribution in the National Emphysema Treatment Trial
DeMeo, Dawn L. , Hoffman, Eric A. , Litonjua, Augusto A. , Lazarus, Ross , Sparrow, David , Benditt, Joshua O., Scanlon, Paul D., Sciurba, Frank C. , Utz, James P., Reilly, John J. , Silverman, Edwin K. , Hersh, Craig P. , Criner, Gerard J. , Make, Barry J. , Martínez, Fernando J. , Hoffman, Eric A

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | March 15, 2007 | Volume: 176 | Issue: 1 | Pages: 42-48

10.1164/rccm.200612-1797oc | PMID 17363767 Get It

Abstract Rationale Computed tomography (CT) scanning of the lung may reduce phenotypic heterogeneity in defining subjects with chronic obstructive pulmonary disease (COPD), and allow identification of genetic determinants of emphysema severity and distribution. Objectives We sought to identify genes associated with CT scan distribution of emphysema in individuals without α1-antitrypsin deficiency but with severe COPD. Methods We evaluated baseline CT densitometry phenotypes in 282 individuals with emphysema enrolled in the Genetics Ancillary Study of the National Emphysema Treatment Trial, and used regression models to identify genetic variants associated with emphysema distribution. Measurements and Main Results Emphysema distribution was assessed by two methods—assessment by radiologists and by computerized density mask quantitation, using a threshold of −950 Hounsfield units. A total of 77 polymorphisms in 20 candidate genes were analyzed for association with distribution of emphysema. GSTP1, EPHX1, and MMP1 polymorphisms were associated with the densitometric, apical-predominant distribution of emphysema (p value range = 0.001–0.050). When an apical-predominant phenotype was defined by the radiologist scoring method, GSTP1 and EPHX1 single-nucleotide polymorphisms were found to be significantly associated. In a case–control analysis of COPD susceptibility limited to cases with densitometric upper-lobe–predominant cases, the EPHX1 His139Arg single-nucleotide polymorphism was associated with COPD (p = 0.005). Conclusions Apical and basal emphysematous destruction appears to be influenced by different genes. Polymorphisms in the xenobiotic enzymes, GSTP1 and EPHX1, are associated with apical-predominant emphysema. Altered detoxification of cigarette smoke metabolites may contribute to emphysema distribution, and these findings may lead to further insight into genetic determinants of emphysema.